Brief title: FLO/FLP
Design: Randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
No of patients: 180
Randomized, open, multicentre phase II study comparing FLO with FLP chemotherapy in patients with advanced gastric cancer or adenocarcinoma of the esophagogastric junction without palliative chemotherapy. Primary outcome measure was survival after six months. Secondary outcome measures were toxicities, overall survival and response rate.
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26